RESUMO
Changes in the structure and cellular composition of aggregated lymphoid nodules (ALN, Peyer's patches) of the small intestine and in mesenterial lymph nodes (MLN) were studied in 82 female Wistar rats 7, 14 and 21 days following a single intraperitoneal injection of a complex of antineoplastic drugs (cyclophosphamide, adriamycine, vincristine and prednisolone). In ALN and MLN lymphoid nodules the administration of antineoplastic drugs resulted in the decrease of the number of blast cells and mitotically dividing cells, suggesting the suppression of B-cell proliferation and differentiation. At the same time, the dimensions of germinal centers in ALN lymphoid nodules were reduced, while their mantle zone size remained unchanged. On the contrary, in MLN lymphoid nodules, mantle zone was reduced, while germinal center dimensions remained constant. Possible reasons of these differences in responses of the immune organs studied to chemotherapy, are discussed.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia , Tecido Linfoide/efeitos dos fármacos , Animais , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Linfócitos B/efeitos dos fármacos , Linfócitos B/patologia , Linfócitos B/ultraestrutura , Ciclofosfamida/administração & dosagem , Doxorrubicina/administração & dosagem , Feminino , Linfonodos/efeitos dos fármacos , Linfonodos/patologia , Linfonodos/ultraestrutura , Tecido Linfoide/patologia , Tecido Linfoide/ultraestrutura , Mesentério , Nódulos Linfáticos Agregados/efeitos dos fármacos , Nódulos Linfáticos Agregados/patologia , Nódulos Linfáticos Agregados/ultraestrutura , Prednisolona/administração & dosagem , Ratos , Ratos Wistar , Vincristina/administração & dosagemRESUMO
A link between HLA allelic variants and long-term results of surgery for gastric tumors was established on the basis of a 10-years follow-up of 112 cancer patients (stage I-II--37.9, III-IV--62.1%; radical surgery--44.6%). HLA class I was studied in a lymphocytotoxic test; HLA class II--gene DRBI specificity using polymerase chain reaction of peripheral blood cell DNA. The control group included healthy subjects living in the city of Novosibirsk (n = 341). High frequency of antigens HLA-B41, -DR1, -DR7 (p < 0.01) co-occurred with HLA-A2, -B12, -B13 and -B18 presence (p < 0.05) in breast cancer patients. Clinical manifestations of cancer were shown to develop in HLA-A1, -B8, -B15, -DR3 and -DR5 carriers at early stages. Tumor development at later stages (III-IV) was associated with HLA-A2, -B12, -B17, -B35, -B41 and -DR7. A link was registered between lethality rate, on the one hand, and HLA-A3, -B22, and, in particular, DR4, on the other, while remission of more than 7-years--with HLA-A11, -B13, -B21 and -DR5. HLA-B22/DR3 phenotype involved worse prognosis in radically-treated patients whereas that of HLA-B8/DR3--a better one.
